ClinicalTrials.gg
CompletedNCT05982106Updated Aug 8, 2023

To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects

A Phase 1 interventional study of TQ05105 Tablets in Myelofibrosis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Jul 2021, registered Jul 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited — 3 open to participants now, 5 under way, none of them phase 3. Primary Myelofibrosis · Sino Biopharmaceutical Limited.

Enrollment
9th of 10
16 · median 28
Started
2021
the only one that year
Phase 1
7 of 10
1 open now
Registered
1st of 10
by date

Among the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, this one is the 9th largest by enrollment, is the only one that started in 2021, is one of 7 in phase 1, and was the 1st registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

TQ05105 is a class 1 new drug with a new chemical structure developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. It is a Janus Kinase 2 (JAK2)inhibitor and can be used to treat JAK2 target-related diseases. This study is a randomized, open-label, single-center, two-cycle, two-crossover Phase I clinical trial evaluating the effect of food on the pharmacokinetics of TQ05105 tablets in healthy adult subjects. Pharmacokinetic effects and safety after oral administration of TQ05105 tablets.

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 Sign the form before the test, and fully understand the test content, process and possible adverse reactions;
  • 2 Able to communicate well, understand and complete the research in accordance with the requirements of the experimental protocol;
  • 3 Male and female subjects aged 18 to 65 (including 18 and 65 years old);
  • 4 (BMI) ≥ 18 and ≤ 28kg/m2, and male weight ≥ 50 kg and female weight ≥ 45 kg;
  • 5 Health status: no history of heart, liver, kidney, digestive tract, nervous system, mental abnormalities and metabolic abnormalities, and physical examination showed normal or abnormal blood pressure, heart rate, , respiratory system, liver, kidney function and blood picture without clinical significance;
  • 6 The subjects have no pregnancy plans and voluntarily take effective measures from 2 weeks before the administration to at least 6 months after the last use of the study drug.

Exclusion criteria

Exclusion Criteria:

  • 1 Patients with neuropsychiatric system, respiratory system, cardiovascular system, digestive tract system, blood-lymphatic system, liver and kidney insufficiency, endocrine system, musculoskeletal system disease or other diseases in the past, and the researcher judges that the past medical history may have an adverse effect on the drug. Metabolic or safety effects;
  • 2 Those with allergic constitution or a history of two or more food or drug allergies in the past;
  • 3 Those with multiple factors that affect oral drugs (such as inability to swallow, gastrointestinal diseases);
  • 4 Taking any prescription, over-the-counter, vitamin product or herbal medicine within 1 month before taking the study drug;
  • 5 Take inhibitors or inducers within 1 month before screening or before study medication;
  • 6 Those who have taken special diets (including grapefruit, etc.) or exercised vigorously within 14 days before screening, or have other factors that affect drug absorption, distribution, metabolism, and excretion;
  • 7 aboratory examinations during the screening period are abnormal and have clinical significance;
  • 8 Blood donation or massive blood loss (> 450mL) within 3 months before taking the study drug;
  • 9 Participated in any drug clinical trial within 3 months before taking the study drug;
  • 10 Smoking more than 5 cigarettes per day within 3 months before the test;
  • 11 Positive breath test for alcohol or a history of alcohol abuse within 2 weeks before screening (drinking 14 units of alcohol per week: 1 unit = 360mL of beer or 45mL of spirits with an alcohol content of 40% or 150mL of wine);
  • 12 Those who are positive for drug screening or have used drugs in the 3 months before the test;
  • 13 Inability to tolerate venipuncture for blood collection or poor vascular condition;
  • 14 Subjects have a history of herpes zoster within 1 month before screening;
  • 15 The subject is unable to complete the trial due to personal reasons;
  • 16 Other investigators deem it unsuitable for enrollment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    TQ05105 Tablets (fasted)

    TQ05105 tablets was administered on fasted state in the first cycle for Group A and the second cycle for Group B.

    Drug: TQ05105 Tablets

  • Experimental
    TQ05105 Tablets (fed)

    TQ05105 tablets was administered on fed state in the second cycle for Group A and the first cycle for Group B.

    Drug: TQ05105 Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the drug-time curve (AUC)

    Area under the drug-time curve

    Time frame: 1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration

  2. Maximum Concentration (Cmax)

    Maximum concentration

    Time frame: 1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration

Secondary outcomes

  1. Time to maximum concentration following drug administration (Tmax)

    Time to maximum concentration following drug administration

    Time frame: 1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration

  2. Apparent terminal elimination half-life following drug administration (t1/2)

    Apparent terminal elimination half-life following drug administration

    Time frame: 1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration

  3. Apparent volume of distribution (Vd/F)

    Apparent volume of distribution

    Time frame: 1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration

  4. Clearance rate (CL/F)

    Clearance rate

    Time frame: 1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration

  5. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to 24 hours after administration

  6. Body temperature

    Monitor the safety indicators of subjects during the trial

    Time frame: 1 hour before administration and 1, 4, 12, 24 hours after administration

  7. Pulse

    Monitor the safety indicators of subjects during the trial

    Time frame: 1 hour before administration and 1, 4, 12, 24 hours after administration

  8. Blood pressure

    Monitor the safety indicators of subjects during the trial

    Time frame: 1 hour before administration and 1, 4, 12, 24 hours after administration

07

Study locations

1 site
  • Affiliated Hospital of Changchun University of Traditional Chinese Medicine
    Changchun, Jilin 130103, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jul 2021, 0 months.

Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Aug 8, 2023
StartActual
Jul 19, 2021
Primary completionActual
Jul 28, 2021
CompletionActual
Jul 28, 2021
Last update
Aug 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05982106
Responsible party
Sponsor
First posted
Aug 8, 2023
Start date
Jul 19, 2021
Primary completion
Jul 28, 2021
Completion
Jul 28, 2021
Last update
Aug 8, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JAK2 Inhibitor TQ05105

Start the discussion